Core Viewpoint - The company announced that three of its self-developed clinical products, TY-302, TY-2699a, and TY-0540, have been accepted for presentation at the 2025 European Society for Medical Oncology (ESMO) conference, with detailed data to be published in the official ESMO journal, "Annals of Oncology" [1][2]. Group 1: Product Details - TY-302 is a potent, selective oral CDK4/6 inhibitor developed for treating advanced solid tumors such as breast and prostate cancer. It targets CDK4/6 to inhibit the phosphorylation of Rb, preventing cancer cell proliferation. Preclinical studies indicate lower gastrointestinal side effects and more controllable hematological toxicity compared to the leading CDK4/6 inhibitor, palbociclib. Phase I clinical data show significant efficacy and good safety when combined with tamoxifen for HR+/HER2- advanced breast cancer patients [1]. - TY-2699a is a selective CDK7 inhibitor aimed at treating advanced/metastatic solid tumors. Preclinical studies confirm its ability to precisely inhibit cancer cell growth at doses that do not affect normal cells. Initial clinical data demonstrate excellent safety and preliminary efficacy at similar dose levels. The data presented is from a Phase I multicenter monotherapy dose-escalation trial, with ongoing expansion trials for triple-negative breast cancer (TNBC) [2]. - TY-0540 is a selective CDK2 inhibitor intended for treating breast cancer, ovarian cancer, and other solid tumors. It shows strong inhibitory effects on key targets such as CDK2/CycA2 and CDK2/CycE1, while also exhibiting activity against related targets CDK4/CycD1 and CDK6/CycD3. Both preclinical and clinical studies indicate significant inhibitory effects and good safety profiles in various solid tumors, including models resistant to palbociclib. The data presented is from a Phase I multicenter open-label clinical trial, with ongoing Phase Ib/II studies [2].
同源康医药-B(02410.HK)：TY-302、TY-2699a及TY-0540的I期临床试验结果获2025年欧洲肿瘤内科学会(ESMO)大会以壁报形式收录